Dopamine D2 receptor scintigraphy of pituitary adenomas is feasible by single-photon emission computed tomography using123I-S-(-)-N-[(1- ethyl-2-pyrrolidinyl)methyl]-2-hydroxy-3-iodo-6-methoxybenzamide (123I-IBZM) and123I-epidepride.123I-epidepride is generally superior to123I-IBZM for the visualization of D2 receptors on pituitary macroadenomas. However,123I-IBZM and123I-epidepride scintigraphy are generally not useful to predict the response to dopaminergic treatment in pituitary tumour patients. These techniques might allow discrimination of non-functioning pituitary macroadenomas from other non-tumour pathologies in the sellar region. Dopamine D2 receptors on pituitary tumours can also be studied using positron emission tomography with11C-N-raclopride and11C-N-methylspiperone.

Additional Metadata
Persistent URL dx.doi.org/10.1530/eje.1.02349, hdl.handle.net/1765/36296
Journal European Journal of Endocrinology. Supplement
Citation
de Herder, W.W, Reijs, A.E.M, Feelders, R.A, van Aken, M.O, Krenning, E.P, van der Lely, A-J, & Kwekkeboom, D. (2007). Diagnostic imaging of dopamine receptors in pituitary adenomas. In European Journal of Endocrinology. Supplement (Vol. 156). doi:10.1530/eje.1.02349